🇺🇸 Calcipotriene + Betamethasone Dipropionate in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 15

Most-reported reactions

1. Psoriasis — 3 reports (20%)
2. Diarrhoea — 2 reports (13.33%)
3. Nausea — 2 reports (13.33%)
4. Pain In Extremity — 2 reports (13.33%)
5. Alanine Aminotransferase Increased — 1 report (6.67%)
6. Appendicitis — 1 report (6.67%)
7. Aspartate Aminotransferase Increased — 1 report (6.67%)
8. Atrial Fibrillation — 1 report (6.67%)
9. Back Pain — 1 report (6.67%)
10. Breast Cancer — 1 report (6.67%)

Source database →

Frequently asked questions

Is Calcipotriene + Betamethasone Dipropionate approved in United States?

Calcipotriene + Betamethasone Dipropionate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Calcipotriene + Betamethasone Dipropionate in United States?

Odense University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.